Literature DB >> 28375452

Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

Laurie S Davis1, Andreas M Reimold1,2.   

Abstract

This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mechanisms driving disease pathogenesis combined with recent advances in medical science are predicted to enable accelerated progress towards improved SLE diagnosis and personalized approaches to treatment.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  B cells; biological therapies; clinical trials and methods; immunotherapy; systemic lupus erythematosus and autoimmunity

Mesh：

Substances：

Year:  2017        PMID： 28375452      PMCID： PMC5850311          DOI： 10.1093/rheumatology/kew417

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


  153 in total

Review 1.  The emerging role of complement inhibitors in transplantation.

Authors:  Véronique Frémeaux-Bacchi; Christophe M Legendre
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

Review 2.  Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.

Authors:  Morton A Scheinberg; Colin M Hislop; Renee S Martin
Journal:  Expert Opin Biol Ther       Date:  2016       Impact factor: 4.388

3.  Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Authors:  Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta
Journal:  Arthritis Rheum       Date:  2013-09

4.  BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.

Authors:  Viktor Roschke; Svetlana Sosnovtseva; Christopher D Ward; June S Hong; Rodger Smith; Vivian Albert; William Stohl; Kevin P Baker; Stephen Ullrich; Bernardetta Nardelli; David M Hilbert; Thi-Sau Migone
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.

Authors:  J A James; X R Kim-Howard; B F Bruner; M K Jonsson; M T McClain; M R Arbuckle; C Walker; G J Dennis; J T Merrill; J B Harley
Journal:  Lupus       Date:  2007       Impact factor: 2.911

6.  Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.

Authors:  Kendra A Young; Melissa E Munroe; Joel M Guthridge; Diane L Kamen; Timothy B Niewold; Gary S Gilkeson; Michael H Weisman; Mariko L Ishimori; Jennifer Kelly; Patrick M Gaffney; Kathy H Sivils; Rufei Lu; Daniel J Wallace; David R Karp; John B Harley; Judith A James; Jill M Norris
Journal:  Ann Rheum Dis       Date:  2016-06-09       Impact factor: 19.103

7.  Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes.

Authors:  Hesham Al Maimouni; Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

Review 8.  CD22 and autoimmune disease.

Authors:  Thomas Dörner; Anthony Shock; Kenneth G C Smith
Journal:  Int Rev Immunol       Date:  2012-10       Impact factor: 5.311

Review 9.  Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.

Authors:  B Duxbury; C Combescure; C Chizzolini
Journal:  Lupus       Date:  2013-10-17       Impact factor: 2.911

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
View more
  12 in total

1.  Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Authors:  F Fioredda; E Cappelli; A Mariani; A Beccaria; E Palmisani; A Grossi; I Ceccherini; R Venè; C Micalizzi; M Calvillo; F Pierri; I Mancini; F Peyvandi; F Corsolini; C Dufour; M Miano
Journal:  Blood Adv       Date:  2019-11-12

Review 2.  Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.

Authors:  Xiaozhen Mu; Chenchen Wang
Journal:  Curr Rheumatol Rep       Date:  2018-07-28       Impact factor: 4.592

Review 3.  Pathogenesis and treatment of autoimmune rheumatic diseases.

Authors:  Eric Liu; Andras Perl
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

4.  Blood Genomics Identifies Three Subtypes of Systemic Lupus Erythematosus: "IFN-High," "NE-High," and "Mixed".

Authors:  Mintian Cui; Taotao Li; Xinwei Yan; Chao Wang; Qi Shen; Hongbiao Ren; Liangshuang Li; Ruijie Zhang
Journal:  Mediators Inflamm       Date:  2021-07-01       Impact factor: 4.711

5.  Cytokine and autoantibody clusters interaction in systemic lupus erythematosus.

Authors:  Yovana Pacheco; Julián Barahona-Correa; Diana M Monsalve; Yeny Acosta-Ampudia; Manuel Rojas; Yhojan Rodríguez; Juliana Saavedra; Mónica Rodríguez-Jiménez; Rubén D Mantilla; Carolina Ramírez-Santana; Nicolás Molano-González; Juan-Manuel Anaya
Journal:  J Transl Med       Date:  2017-11-25       Impact factor: 5.531

Review 6.  Recent advances in the management of systemic lupus erythematosus.

Authors:  Savino Sciascia; Massimo Radin; Dario Roccatello; Giovanni Sanna; Maria Laura Bertolaccini
Journal:  F1000Res       Date:  2018-06-29

Review 7.  Emerging immunotherapies for autoimmune kidney disease.

Authors:  Mary Helen Foster; Jeffrey Robinson Ord
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 4.526

Review 8.  SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.

Authors:  Gisela Canedo-Marroquín; Farides Saavedra; Catalina A Andrade; Roslye V Berrios; Linmar Rodríguez-Guilarte; María C Opazo; Claudia A Riedel; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

9.  Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome.

Authors:  Zhuochao Zhou; Yijun You; Fan Wang; Yue Sun; Jialin Teng; Honglei Liu; Xiaobing Cheng; Yutong Su; Hui Shi; Qiongyi Hu; Huihui Chi; Jinchao Jia; Liyan Wan; Tingting Liu; Mengyan Wang; Ce Shi; Chengde Yang; Junna Ye
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 7.561

10.  Case Report: Psychopathological Syndromes in the Course of Lupus Erythematosus and the Co-occurrence of Lupus Erythematous With Mental Disorders.

Authors:  Ewa Stelmach; Jolanta Masiak
Journal:  Front Psychiatry       Date:  2021-06-24       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.